drugset / Trial / NCT04503746

A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic Periodontitis

NCT04503746 ↗

Phase 2 Completed 117 enrolled AngioLab, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to evaluate efficacy and safety of ALH-L1005 in patients with chronic periodontitis

Timeline

Start
2020-07-16
Primary completion
2021-12-13
Completion
2021-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ALH-L1005 Unknown 600 mg —
Subject ALH-L1005 Unknown 1200 mg —

Indications